Domača stranCVAC • NASDAQ
add
CureVac BV
3,26 $
Po zaprtju:(2,15 %)−0,070
3,19 $
Konec trgovanja: 12. jul., 19:47:42 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
3,27 $
Dnevni razpon
3,17 $ - 3,39 $
Letni razpon
2,22 $ - 10,55 $
Tržna kapitalizacija
731,24 mio. USD
Povprečni obseg
1,45 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | mar. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 12,37 mio. | 73,56 % |
Stroški poslovanja | 47,77 mio. | −1,92 % |
Čisti dohodek | −70,55 mio. | −22,87 % |
Čista dobičkovnost prihodkov | −570,22 | 29,20 % |
Earnings per share | −0,31 | −14,81 % |
EBITDA | −72,22 mio. | −28,15 % |
Efektivna davčna stopnja | −0,95 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | mar. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 300,15 mio. | −51,39 % |
Skupna sredstva | 690,43 mio. | −29,09 % |
Skupne obveznosti | 243,52 mio. | −6,44 % |
Celoten lastniški kapital | 446,91 mio. | — |
Shares outstanding | 224,31 mio. | — |
Razmerje P/B | 1,64 | — |
Donosnost sredstev | −26,07 % | — |
Donosnost kapitala | −36,84 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | mar. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −70,55 mio. | −22,87 % |
Denar iz dejavnosti | −96,55 mio. | 3,04 % |
Denar iz naložb | −5,09 mio. | 61,34 % |
Denar iz financiranja | −1,12 mio. | −100,48 % |
Neto sprememba denarnih sredstev | −102,30 mio. | −184,04 % |
Prost denarni tok | −68,47 mio. | 25,88 % |
Vizitka
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Generalni direktor
Datum ustanovitve
2000
Spletno mesto
Zaposleni
1.086
